Overview
In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.
Eligibility
Inclusion Criteria:
- lymphoid malignancies
- donor available: HLA matched sibling, unrelated donor or haplo-identical related donor.
- patients with ECOG <3
Exclusion Criteria:
- inform consent not provided
- ECOG >=3
- poor liver function (enzyme >2N or bilirubin >2N)
- poor renal function (Scr >2N)
- poor cardiac function (EF <45%)